Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of "Moderate Buy" by Brokerages
Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has received an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $21.00.
据Marketbeat.com报道，异基因治疗公司(纳斯达克代码：ALLO-GET Rating)目前覆盖该公司的12家评级公司的平均评级为“中等买入”。一名投资分析师对该股的评级为卖出，一名分析师给出了持有评级，九名分析师给出了该公司的买入评级。在过去一年里追踪该股的经纪商中，1年的平均目标价为21.00美元。
Several analysts recently issued reports on ALLO shares. HC Wainwright reduced their price target on shares of Allogene Therapeutics from $43.00 to $29.00 and set a "buy" rating on the stock in a research report on Monday, November 21st. Bank of America lowered shares of Allogene Therapeutics from a "buy" rating to an "underperform" rating and reduced their price target for the stock from $24.00 to $9.00 in a research report on Monday, December 12th. Oppenheimer reissued an "outperform" rating and issued a $32.00 price objective on shares of Allogene Therapeutics in a research note on Thursday, December 1st. JPMorgan Chase & Co. raised shares of Allogene Therapeutics from a "neutral" rating to an "overweight" rating and dropped their price objective for the company from $20.00 to $11.00 in a research note on Tuesday. Finally, Robert W. Baird raised shares of Allogene Therapeutics from a "neutral" rating to an "outperform" rating and set a $12.00 price objective for the company in a research note on Friday, January 6th. They noted that the move was a valuation call.
几位分析师最近发布了关于Allo股票的报告。HC Wainwright在11月21日星期一的一份研究报告中将他们对异体基因治疗公司股票的目标价从43.00美元下调至29.00美元，并对该股设定了“买入”评级。美国银行在12月12日(星期一)的一份研究报告中将allgene Treeutics的股票评级从“买入”下调至“表现不佳”，并将该股的目标价从24.00美元下调至9.00美元。奥本海默在12月1日星期四的一份研究报告中重新发布了“跑赢大盘”的评级，并为异基因治疗公司的股票发布了32.00美元的目标价。周二，摩根大通在一份研究报告中将阿罗吉恩治疗公司的股票评级从中性上调至增持，并将该公司的目标价从20.00美元下调至11.00美元。最后，罗伯特·W·贝尔德在1月6日星期五的一份研究报告中将异基因治疗公司的股票评级从中性上调至“跑赢大盘”，并为该公司设定了12.00美元的目标价。他们指出，此举是一次估值预测。
Insider Activity
内幕活动
In other news, General Counsel Veer Bhavnagri sold 5,602 shares of the firm's stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $7.53, for a total transaction of $42,183.06. Following the completion of the transaction, the general counsel now owns 583,677 shares of the company's stock, valued at $4,395,087.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 29.80% of the company's stock.
在其他新闻方面，总法律顾问Veer Bhavnagri在12月15日星期四的一次交易中出售了5602股该公司的股票。这些股票以7.53美元的平均价格出售，总成交额为42,183.06美元。交易完成后，总法律顾问现在拥有该公司583,677股股票，价值4,395,087.81美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过此超链接。内部人士持有该公司29.80%的股份。
Hedge Funds Weigh In On Allogene Therapeutics
对冲基金参与同种异体基因治疗
Allogene Therapeutics Trading Up 15.7 %
同种异体基因治疗药物交易上涨15.7%
NASDAQ ALLO opened at $7.94 on Wednesday. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.61 and a beta of 0.71. The firm's 50 day simple moving average is $7.70 and its 200 day simple moving average is $10.81. Allogene Therapeutics has a 1 year low of $5.41 and a 1 year high of $17.49.
纳斯达克周三开盘报7.94美元。该公司市值11.5亿美元，市盈率为-3.61倍，贝塔系数为0.71。该公司的50日简单移动均线为7.70美元，200日简单移动均线为10.81美元。异基因治疗公司的一年低点为5.41美元，一年高位为17.49美元。
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.04. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.01 million. Allogene Therapeutics had a negative net margin of 126,580.16% and a negative return on equity of 37.74%. During the same quarter last year, the business posted ($0.57) EPS. On average, equities research analysts forecast that Allogene Therapeutics will post -2.38 earnings per share for the current year.
异基因治疗公司(纳斯达克：ALLO-GET评级)最近一次公布季度收益结果是在11月2日星期三。该公司公布本季度每股收益(EPS)为0.58美元，比普遍预期的0.62美元高出0.04美元。该业务本季度营收为5万美元，而分析师预期为10万美元。同种基因治疗公司的净利润率为负126580.16%，净资产回报率为负37.74%。去年同一季度，该业务公布了每股收益(0.57美元)。平均而言，股票研究分析师预测，异基因治疗公司本年度的每股收益将达到2.38美元。
About Allogene Therapeutics
关于同种异体基因疗法
(Get Rating)
(获取评级)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
异体基因治疗公司是一家临床阶段免疫肿瘤学公司，开发并商业化用于癌症治疗的基因工程同种异体T细胞疗法。它开发、制造和商业化UCART19，这是一种同种异体嵌合抗原受体(CAR)T细胞产品，用于治疗R/R CD19阳性B细胞ALL的儿童和成人患者。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
- 免费获取StockNews.com关于同种异体基因治疗的研究报告(ALLO)
- 柔顺治疗公司的差距增加了34%：未来还会有更多的好处吗？
- 2023年初裁员将如何影响这5只生物科技股？
- Baudax Bio投资者在经历了70%的飙升后，痛苦是否已经结束？
- 火箭实验室的首次美国发射将把斯托克送入平流层吗？
- 2023年响亮登场的3只零售股
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《同种异体基因治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对异种基因治疗公司和相关公司评级的每日简要摘要。